news
Top biopharma firms report Q3 market capitalisation decline
The top 20 biopharma companies averaged a market capitalisation decline of $3.45 trillion in Q2 to $3.14 trillion in Q3 2022, says GlobalData.
List view / Grid view
Vertex
news
Kaftrio® with ivacaftor approved by EC to treat children with cystic fibrosis
Children with cystic fibrosis aged six to11 years could benefit from Kaftrio® in combination with ivacaftor, as a treatment targeting the underlying cause of the disease.
news
First annual Pharmaceutical Invention Index released
The first Pharmaceutical Invention Index, which looks at the breadth and depth of novel agents currently being developed within the most innovative pharma pipelines, has been released.
news
Vertex in long-term reimbursement agreement with ROI for CF medicines
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
article
Exploring the need for mutation-specific treatments in cystic fibrosis
1 July 2016 | By Caroline Richards, Editor, European Pharmaceutical Review
Here, Caroline Richards, Editor of European Pharmaceutical Review, discusses cystic fibrosis and the treatment options that are currently available or in development...
news
EC grants marketing authorisation for cystic fibrosis drug Orkambi
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...
news
FDA approves cystic fibrosis treatment Orkambi
3 July 2015 | By Victoria White
The FDA has approved Vertex’s Orkambi, the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation...
news
Data from two Phase 3 studies of cystic fibrosis investigational medicine Orkambi published
18 May 2015 | By Victoria White
Data from two Phase 3 studies of Orkambi, an investigational medicine designed to treat the underlying cause of cystic fibrosis, have been published...
news
Regeneron led the way for mid-cap biotech research and development spending in 2014
24 April 2015 | By Victoria White
The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, says leading research and consulting firm GlobalData.
